New York, NY – Investors who purchased securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October 10, 2023, and December 26, 2025, may be eligible for compensation, according to a notice from Rosen Law Firm. The firm is encouraging those who experienced losses during this period, known as the “Class Period,” to secure legal counsel before the lead plaintiff deadline of April 7, 2026. This action stems from allegations of misleading statements made by the company regarding its drug development and manufacturing processes.
The core of the issue, as outlined in a recently filed class action lawsuit, centers on claims that Inovio misrepresented the status of its CELLECTRA device manufacturing and the likelihood of submitting a Biologics License Application (BLA) for its INO-3107 drug to the U.S. Food and Drug Administration (FDA) by the second half of 2024. The lawsuit further alleges that the company lacked sufficient data to support its claims regarding accelerated or priority review eligibility for INO-3107, ultimately overstating the drug’s potential. These allegations, if proven, suggest investors were not provided with a complete and accurate picture of the company’s prospects.
Rosen Law Firm’s Role and Investor Options
Rosen Law Firm, a global investor rights firm, is acting as counsel in this case and is seeking to identify a lead plaintiff – an investor who will represent the interests of all class members in the litigation. Investors who wish to be considered for this role must file a motion with the Court no later than April 7, 2026. It’s critical to note that serving as lead plaintiff is not required to potentially benefit from any future recovery. Investors can similarly choose to remain absent class members and still potentially receive compensation if the lawsuit is successful.
The firm emphasizes the importance of selecting experienced legal counsel in securities class action cases. They caution investors that some firms may act as “middlemen,” referring clients to other firms that actually handle the litigation. Rosen Law Firm highlights its own track record, noting its success in securing substantial settlements for investors, including what it claims was the largest ever securities class action settlement against a Chinese Company. The firm was also ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked among the top firms in this field since 2013. In 2020, founding partner Laurence Rosen was recognized by Law360 as a “Titan of Plaintiffs’ Bar.”
Details of the Allegations Against Inovio Pharmaceuticals
The lawsuit details five key alleged misrepresentations made by Inovio Pharmaceuticals throughout the Class Period. These include claims that:
- Manufacturing processes for the CELLECTRA device were deficient.
- The company was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024.
- Inovio lacked sufficient information to justify accelerated or priority review for INO-3107.
- The overall regulatory and commercial prospects of INO-3107 were overstated.
- As a result of these issues, the company’s public statements were materially false and misleading.
The lawsuit contends that when these issues came to light, investors suffered damages as a result. The specific nature of those damages would be determined through the course of the litigation.
How to Join the Class Action
Investors who purchased Inovio Pharmaceuticals (NASDAQ: INO) securities between October 10, 2023, and December 26, 2025, and experienced losses are encouraged to contact Rosen Law Firm for more information. They can do so by visiting https://rosenlegal.com/submit-form/?case_id=52847, calling Phillip Kim, Esq. Toll-free at 866-767-3653, or emailing [email protected].
It’s crucial to remember that no class has been certified at this time. Which means that investors are not yet represented by counsel unless they retain their own. Investors have the right to choose their own legal representation or remain an absent class member. Participation as a lead plaintiff is not a prerequisite for potential recovery.
Rosen Law Firm provides updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm, and on Facebook: https://www.facebook.com/rosenlawfirm/.
Disclaimer: This article is for informational purposes only and does not constitute legal advice. Investors should consult with their own legal counsel to determine their rights and options.
The next key date in this case is the lead plaintiff deadline of April 7, 2026. Investors who wish to be considered for the lead plaintiff role must file a motion with the Court by this date. Further updates on the case will likely be available through Rosen Law Firm and court filings. We will continue to follow this story and provide updates as they develop into available.
Have questions or comments about this story? Share your thoughts below.
